- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Epigenetics

Epigenetics explains how cells are able to use different parts of their DNA at different times. Epigenetic modifications made to our DNA underpin many important processes in our bodies, and can be corrupted in disease.
Our epigenetics researchers aim to unravel how epigenetic changes influence healthy and diseased cells, with a goal of better treatments for diseases.
Our epigenetics research
Our research in the field of epigenetics aims to:
- Discover new proteins that either package or epigenetically modify our DNA.
- Reveal how epigenetic changes control the development and function of different cell types in health and disease.
- Develop new strategies that treat disease by altering the epigenetic control of genes.
What is epigenetics?
Epigenetics examines how our body manages to create all of our different cell types – such as white blood cells, muscle cells and skin cells – from the same genetic code. It studies how chemical changes, called ‘epigenetic modifications’ switch genes on or off.
Our genome, made of DNA, contains the instructions for how our cells behave. Different cells in our body function in distinct ways because of variations in the proteins made by each cell. The proteins are produced under instruction from genes. Switching different genes on or off affects which particular proteins are produced. For example, red blood cells produce haemoglobin to transport oxygen, whereas skin cells make elastin to keep our skin elastic.
DNA consists of four ‘letters’ called bases. It is the sequence of bases that makes the instructions within genes. Changes in the order of the bases changes the proteins that are produced.
Epigenetic modifications are chemical changes to DNA and to certain proteins, called histones, that DNA wraps around. The DNA and histones together are called ‘chromatin’.
Chemical changes influence whether the chromatin is:
- ‘Open’ or packed loosely, allowing genes to be active, or
- ‘Closed’ or packed tightly, inactivating the genes.
Epigenetic modifications are reversible: a cell can switch off a gene at one point in time, and switch it back on later. The trigger to open or close a particular section of DNA can be:
- An external signal received by the cell, such as a hormone binding to a receptor, or a change in a nutrient.
- An internal change in the cell, such as the cell preparing to divide.
When a cell divides, the ‘parent’ cell’s epigenetic state can be maintained in the daughter cells. This means that a trigger at one point in time can influence how a cell behaves at a later time. It also means that when a certain type of cell divides it produces another cell of the same type. Thus, a liver cell divides into two liver cells, not into any other type of cell.
The environment can also influence epigenetic modifications. In particular, it appears that changes to a mother’s diet are experienced by the developing foetus, and can influence how epigenetic modifications are established during development in the womb. This can influence the disease sensitivities of the person into adulthood.
Epigenetic modifiers
The proteins that make epigenetic changes to chromatin are called ‘epigenetic modifiers’. These include:
- Histone acetyltransferases (HATs), histone methyltransferases and histone deacetylases (HDACs) and histone demethylases that modify histone proteins.
- DNA methyltransferases, which modify certain bases in DNA, and a set of proteins including TET proteins that undo these modifications.
Discovering new epigenetic modifiers is a goal of our epigenetics research.
X-inactivation
Male and female mammals differ at the genetic level:
- Female cells contain two X chromosomes.
- Male cells contain one X and one Y chromosome.
Having two X chromosomes active within a cell is toxic. Therefore, during development female cells apply epigenetic changes to permanently close down all the genes on one X chromosome. This process is called ‘X-inactivation’.
Our researchers are using X-inactivation as a model of epigenetic changes, to discover new ways that genes are switched on and off.
Epigenetics and development
Epigenetic changes explain how one cell can give rise to the complex mix of cells in an adult. During embryonic development, different genes are required at different times, and in different cells. Epigenetic modifications are critical for instructing a cell on which genes it should be using.
Epigenetics and disease
Diseases can occur because of errors within cells. Some of these can be traced to certain changes in the cell’s DNA sequence. It is becoming apparent that specific epigenetic modification in a cell can underlie certain diseases. Our researchers are examining this hypothesis in a number of important conditions including cancer.
Epigenetic changes that alter gene expression occur in cancer cells. These enable the cell to divide uncontrollably and become long lived. Some cancer-causing gene mutations have been found in epigenetic modifiers.
Epigenetic cancer therapies
Epigenetic changes to chromatin can enable the growth of a cancer but, unlike genetic mistakes, these epigenetic changes are reversible. Medications that alter a cancer cell’s epigenetic state have been developed. These interfere with epigenetic modifiers such as the HDACs and DNA methyltransferases. Some of these medications are already in use to treat blood cancers, and are being tested in other cancers.
As research reveals more about epigenetics in health and disease, more strategies to treat disease by altering a diseased cell’s epigenetic state will be developed.
Researchers:
The Human Genome program revealed that it takes 30,000 genes to make a human. But thats not the full story. Marnie Blewitt wants to know more, "How does a cell know which of its 30,000 or so genes should be active and which should be dormant?" she asks.
Coursera course: This course covers the principles of epigenetic control of gene expression, how epigenetic control contributes to cellular differentiation and development, and how it goes wrong in disease.
The discovery of a ‘switch’ that modifies a gene known to be essential for normal heart development could explain variations in the severity of birth defects in children with DiGeorge syndrome.